HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Travere Therapeutics (NASDAQ:TVTX) but has lowered the price target from $32 to $18.
September 22, 2023 | 11:44 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Travere Therapeutics' price target has been lowered from $32 to $18 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. indicates a potential decrease in the short-term value of Travere Therapeutics' stock. However, the maintained 'Buy' rating suggests that the company is still viewed favorably for long-term investment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100